At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 96 target
Drug / intervention
IMMH-010drug
Likely dose
IMMH-010 360mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating IMMH-010 for Malignant Neoplasms. Targeting 96 participants across 1 site.
Detailed Summary
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Neoplasms
CountriesChina
Collaborators--
Timeline
Phase 1UnknownOverdue
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionDec 2024
TodayJul 2026
First PostedApr 13, 2020
Enrollment StartMay 14, 2020
Primary CompletionDec 1, 2024
TodayJul 1, 2026
Enrollment to primary: 4.5 yearsPosted 6.2 years ago
Interventions
IMMH-010drug
After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study.